Updated:
Kissei Pharmaceutical Co.
Kissei Pharmaceutical Co. is a publicly-traded pharmaceutical company based in Matsumoto; the Altss profile covers its classification, headquarters,...
Kissei Pharmaceutical Co.
General information
Firm type
Publicly-traded pharmaceutical company
Location
Region
North America
Country
Japan
City
Matsumoto
Corporate office
Matsumoto, Nagano, Japan
Additional offices
Los Angeles, United States · Sao Paulo, Brazil · Menlo Park, United States
Sector focus
Frequently asked questions
Is Kissei Pharmaceutical a family office or an asset manager?
No. Kissei Pharmaceutical Co. is a publicly traded pharmaceutical company, not a family office or asset manager. Its business is the research, development, manufacture, and sale of prescription drugs, not capital management for external investors.
What are Kissei's key therapeutic areas?
Kissei focuses on oncology (including acute myeloid leukemia), autoimmune diseases (such as ANCA-associated vasculitis), and women's health. It also has products in urology and offers a healthcare division selling food products.
Where is Kissei headquartered?
Kissei's headquarters is in Matsumoto, Nagano, Japan. It also maintains offices in Los Angeles, Menlo Park, and Sao Paulo for global operations.
Does Kissei disclose its AUM or investment portfolio?
No. As a pharmaceuticals company, Kissei does not report AUM. Its financial disclosures focus on revenue, R&D spending, and earnings, not an investment portfolio.
What recent regulatory milestone did Kissei achieve?
In May 2026, Kissei filed a manufacturing and marketing approval application in Japan for olutasidenib to treat acute myeloid leukemia (per Kissei press release, May 2026). The same month it also issued a safety alert for its Tabneos capsules.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: